Poor response to a recombinant hepatitis b vaccine in dialysis patients

Eighty-three dialysis patients were inoculated with 20 μg of the recombinant derived hepatitis B vaccine Engerix-B at 0, 1 and 6 months. Twenty-seven (32·5 %) became seropositive for anti-HBs antibody after the third inoculation. Of the 56 non-responders, 48 received a 40 μg booster dose of vaccine...

Ausführliche Beschreibung